Phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment
- Conditions
- Refractory or relapsed non-Squamous, non-small cell lung cancer
- Registration Number
- JPRN-UMIN000004255
- Lead Sponsor
- Outpatient Oncology Unit, Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Not provided
1) History of using EGFR-TKI 2) Active infectious disease, active other severe diseases (uncontrollable hypertension, diabetes mellitus, cardiac disease, gastro-intestinal hemorrhage etc.) 3) Hemoptysis with 2.5mL or more bleeding tendency 4) Radiological findings of cavity lesion and/or central lesion and/or tumor invasion to major vessels 5) Cardiac and/or brain infarction within 6 months 6) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy 7) Brain metastasis expected bleeding 8) Ineterstitial pneumonitis on Chest CT 9) Impossible oral ingestion 10) Pleural or pericardial effusion, or ascites requiring treatment 11) Inappropriate patients for this study judged by the physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method PFS, OS, Disease Control Rate, AE